A study of an oral pill for angiogenic sarcomas
Part of Cancer clinical trials.
This trial tests an oral medication (ABSK043) that may help your immune system fight certain rare sarcomas. It is for people with intimal sarcoma, head and neck angiosarcoma, or epithelioid hemangioendothelioma that has spread or cannot be removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these sarcoma types: intimal sarcoma, head and neck angiosarcoma, or epithelioid hemangioendothelioma (EHE).
- Your cancer has spread or cannot be removed by surgery.
- You are 18 years or older.
- You can swallow and keep down oral medications.
- You have not had prior treatment with a PD-1 or PD-L1 inhibitor.
- You do not have active brain metastases or a history of pneumonitis or interstitial lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
This Phase 2 trial tests a highly focused radiation treatment to shrink sarcoma that has spread to a limited number of spots in the body. It may help control disease while limiting radiation to healthier tissue.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This Phase 2 trial tests whether combining propranolol (a blood-pressure/heart medicine) with pembrolizumab (an immune therapy) can help people with advanced angiosarcoma or undifferentiated pleomorphic sarcoma that has progressed after first-line chemotherapy. It aims to slow tumor growth and improve outcomes while also studying tumor markers from your biopsy tissue.
This trial tests a new drug, HS-20093, combined with other treatments for people with advanced bone or soft tissue sarcoma. The goal is to see if these combinations can shrink tumors or slow their growth.
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.